Takeda Pharmaceutical (NYSE:TAK) Issues FY 2024 Earnings Guidance

by · The Cerbat Gem

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 3.060-3.060 for the period. The company issued revenue guidance of $30.1 billion-$30.1 billion.

Takeda Pharmaceutical Stock Up 0.1 %

TAK stock opened at $13.96 on Friday. The company has a market capitalization of $44.42 billion, a P/E ratio of 24.07, a price-to-earnings-growth ratio of 0.26 and a beta of 0.54. Takeda Pharmaceutical has a 12 month low of $12.57 and a 12 month high of $15.08. The firm’s fifty day simple moving average is $14.47 and its 200-day simple moving average is $13.79. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74.

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. Takeda Pharmaceutical had a return on equity of 9.88% and a net margin of 6.49%. The business had revenue of $7.75 billion during the quarter. As a group, equities research analysts forecast that Takeda Pharmaceutical will post 1.58 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

(Get Free Report)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Read More